OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OmniAb is approaching its Investor & Analyst Day on October 6, 2026, which serves as the primary near-term catalyst for the stock.
OmniAb will host an Investor & Analyst Day at its headquarters in Emeryville, California. The event will feature presentations from the executive leadership team covering corporate updates, partner programs, the xPloration platform, and technology innovations, followed by a Q&A session and laboratory tours.
Business Wire